UNDERSTANDING OF MOLECULAR ONCOLOGY FOR RADIATION ONCOLOGIST FOR UPCOMING ERA OF CONCURRENT TARGETED RADIOTHERAPY

Baig MQ, Khan Mamun, Vahikar shilpa

Abstract


The process by which normal cells become progressively transformed to malignancy is now known to required the sequential
acquisition of mutations which arises as consequence of damage genome of cells this damage can occurs as a result of
endogenous process such as, The replications of DNA by free radicals generated during metabolic process, DNA can also get
damage by external agents such as ionizing radiations ultraviolet rays as well as chemical carcinogens ,The new discipline by
precisely identifying the molecular basis of differences between normal and malignant cells.
The new concepts of cancer management by targeted therapy alone as well as along radiotherapy further makes this very
important to understanding by oncologist specially radiation oncologist since targeted therapies to target altered genes and if
goes a step ahead to specific targeted therapies for specific types of mutations happened in DNA


Keywords


Targeted Therapy, mutations, Radiotherapy.

Full Text:

PDF

References


-Perkins, N. D. Oncogenes, tumor suppressors and p52 NF-κB. Oncogene 22, 7553–7556 (2003).

-. Lin, L., DeMartino, G. N. & Greene, W. C. Cotranslational biogenesis of NF-κB p50 by the 26S proteasome. Cell 92, 819–828 (1998).

-. Cohen, S., Achbert-Weiner, H. & Ciechanover, A. Dual effects of IκB kinase β-mediated phosphorylation on p105 fate: SCF(β-TrCP)-dependent degradation and SCF(β-TrCP)-independent processing. Mol. Cell. Biol. 24, 475–486 (2004).

-Druker Brian J., et al. "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia." The New England Journal of Medicine 344, no. 14 (2001): 1031–1037.

-Goldman, John M., and Junia V. Melo. "Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia." The New England Journal of Medicine 344, no. 14 (2001): 1084–1086.

-. Nowell, P., J. Rowley, and A. Knudson. "Cancer Genetics, Cytogenetics—Defining the Enemy Within." Nature Medicine 4 (October 1998): 1107–1114.

-. Gerondakis, S., Grossmann, M., Nakamura, Y., Pohl, T. & Grumont, R. Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockouts. Oncogene 18, 6888–6895 (1999).


Refbacks

  • There are currently no refbacks.